Klein et al. showed that GRS failed to improve risk prediction based on PSA alone, either for PCa (AUC = 0.791 vs. 0.792), aggressive cancer (AUC = 0.811 vs. 0.823) or advanced stage (AUC = 0.788 vs. 0.800) [14]. Here, KLK3 is linked to cancer.